Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Global Blood Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2012
Status: Acquired
BioCentury | Apr 10, 2025
Management Tracks
New CEOs at Alterome, Valo and Imbria
Plus: Updates from Harbour BioMed, Ottimo and NeOnc
BioCentury | Sep 26, 2024
Product Development
Sickle cell mechanisms that could fill the hole left by Pfizer’s Oxbryta withdrawal
Following the market withdrawal of Pfizer’s Oxbryta, demand rises for sickle cell therapies with global potential
BioCentury | Feb 2, 2024
Management Tracks
New CFOs for Sanofi, Takeda
Plus: NextPoint names Eisai vet Cheung CEO, Love joins Gilead board and updates from Acumen, Maxion, EnteroBiotix, Remix
BioCentury | Aug 5, 2023
Management Tracks
Dhanak heads to Deciphera
Plus: Quirk takes on CEO role at Terns and an update from Structure
BioCentury | Jul 12, 2023
Management Tracks
Eisai’s Cheung, head of U.S. and Leqembi lead, retiring
Plus: Paterson becomes CEO of Verastem, and updates from
BioCentury | Jun 13, 2023
Management Tracks
Patni becomes chief of R&D at Reata
Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more
BioCentury | Apr 25, 2023
Management Tracks
Sanofi’s Silvestri joins Ipsen as CMO
Plus: Malier leaving Kurma and updates from Harmony, ImmunoGen, Tarsus and more
BioCentury | Mar 13, 2023
Deals
Pfizer believes $43B Seagen deal positions it to fulfill most of 2030 revenue goal
Provided regulators clear deal, pharma sees $10B+ in added revenue from ADC company by early next decade
BioCentury | Mar 8, 2023
Management Tracks
Catalano named CSO at Capsida
Plus: Wagner to head government affairs at ElevateBio and updates from Novo Nordisk, AuraVax, MitoRx and more
BioCentury | Mar 2, 2023
Management Tracks
Stella to be CBO at Strand
Plus: CytoImmune hires Bogatyrenko and updates from Pureos, Centessa and Blackbird
Items per page:
1 - 10 of 140